Susie Shapiro
banner
susie-shapiro.bsky.social
Susie Shapiro
@susie-shapiro.bsky.social
Haematology Consultant (Haemostasis and Thrombosis), Oxford. Views my own.
Link to pre-proof of our review on frailty and frailty syndromes in people with haemophilia doi.org/10.1016/j.jt... Hope to raise awareness to improve screening and current clinical pathways. Much more work needed including for women and for other bleeding disorders!
Redirecting
doi.org
July 31, 2025 at 3:49 PM
Reposted by Susie Shapiro
This #WorldHemophiliaDay, we’re spotlighting the overlooked history of women and hemophilia.

Experts Paula James and Megan Chaigneau join the ISTH Pulse Podcast to share insights from their powerful narrative review in @jthjournal.bsky.social

🎧Listen: bit.ly/3Ept29w #WHD2025
April 16, 2025 at 7:15 PM
Reposted by Susie Shapiro
🎉 Happy #WorldHemophiliaDay!

This year’s theme, “Access for all: Women and girls bleed too,” is a call to action and a reminder that equity in care starts with awareness.

Here’s to building a more inclusive future, together. 💪

#WHD2025 #WeBleedToo #ISTH2025
April 17, 2025 at 3:04 AM
Reposted by Susie Shapiro
Comprehensive review of gene therapy in #hemophilia accepted for publication by Molecular Therapy. The pre-proof is on line at tinyurl.com/3sb4nuex
March 31, 2025 at 8:54 PM
Reposted by Susie Shapiro
Important paper: In patients with cancer and venous thrombosis, extended anticoagulation with low dose Apixaban is as good as full dose Apixaban in preventing thrombosis recurrence and is associated with less bleeding. tinyurl.com/yyfuan35
April 3, 2025 at 8:57 PM
Reposted by Susie Shapiro
In an unprecedented move, the US National Institutes of Health has begun mass terminations of research grants that fund active scientific projects because they no longer meet “agency priorities”.

https://go.nature.com/4bpG2It
Exclusive: NIH to terminate hundreds of active research grants
Studies that touch on LGBT+ health, gender identity and DEI in the biomedical workforce could be terminated, according to documents obtained by Nature.
go.nature.com
March 6, 2025 at 2:25 AM
Reposted by Susie Shapiro
Reposted by Susie Shapiro
Should patients seen in #SDEC #AmbulatoryCare receive #VTE prophylaxis?

Our data #WarwickMedSchool @susie-shapiro.bsky.social show VTE rate in SDEC as high as hospitalised patients.

Ability to ambulate does NOT equal reduced VTE risk.
@ukhahsoc.bsky.social www.sciencedirect.com/science/arti...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
authors.elsevier.com
January 10, 2025 at 4:47 PM
We report 0.9% VTE within 90 days of hospital led acute ambulatory care attendance; similar to traditional medical inpatient care without thromprophylaxis. Further VTE research needed in this rapidly expanding area of medicine#VTE#SDEC @danlasserson.bsky.social
www.sciencedirect.com/science/arti...
Same-day emergency care: a retrospective observational study of the incidence and predictors of venous thromboembolism following hospital-based acute ambulatory medical care
Same-day emergency care (SDEC) is an expanding area of hospital acute medical care. It aims to minimize delays and manage medical emergency patients w…
www.sciencedirect.com
January 10, 2025 at 10:01 AM
Reposted by Susie Shapiro
Pleased to share this perspective on andexanet alfa, now published in @rpth.bsky.social #openaccess🔓
rpthjournal.org/article/S2475-…

I cover blinding, surrogate endpoints, clinical outcomes and thrombosis.

A brief 🧵
January 7, 2025 at 9:49 AM
Reposted by Susie Shapiro
This is your chance to shape the field of #thrombosis and #hemostasis.
Apply for editorial positions at @isth-official.bsky.social journals
@RPTH.bsky.social - Assoc. Editor (2x)
@JTHjournal.bsky.social - Early Career Assoc. Editor (1x)
Deadline is Jan 30!
Apply here 👇
https://buff.ly/3BRloDM
January 9, 2025 at 2:30 PM
Reposted by Susie Shapiro
🩸 Nonneutralizing antibodies (NNAs) in moderate #hemophilia A & B were found in 13% of Nordic patients, linked to >150 exposure days and worse joint outcomes (higher joint health scores, more surgeries). Further research is key to understanding these impacts! @ragnhijm https://buff.ly/3OWH58e
December 15, 2024 at 8:55 AM
Reposted by Susie Shapiro
Until now, (non-approved) emicizumab use in acquired hemophilia A was all about reduction in bleeds and improved convenience for patients and medical staff. Now the German group showed at #ASH2024 that it results in improved survival. Not randomised but impressive.
December 11, 2024 at 8:43 PM
Reposted by Susie Shapiro
Systematic review and meta-analysis of all the AAV gene therapy trials in #hemophilia A and B. Remarkably, 395 patients have had gene therapy for hemophilia during the clinical trials already.
tinyurl.com/47vrua3v
December 11, 2024 at 11:17 PM
Reposted by Susie Shapiro
#Ash24 #hemesky

Very large datasets suggest factor 12 haploinsufficiency substantially reduce venous #thrombosis.

Suggest intravascular pathological clot formation is molecularly different than extra vascular hemostatic clot formation?
December 7, 2024 at 9:31 PM
Reposted by Susie Shapiro
Fascinating study from administrative data showing 20% lower risk of #VTE with GLP-1 receptor agonist use in diabetes in a large population sample.
Association was similar even in people with normal BMI. #ASH24
December 9, 2024 at 1:37 AM
Reposted by Susie Shapiro
90% of women with #vonWillebrandDisease in our pilot study said their periods are heavy, impacting physical and general daily activities. We want to help change this. Can you help us? If you live with von Willebrand’s, find out more about our survey here: loom.ly/yIk8Rwg
#HemeSky #MedSky
December 9, 2024 at 7:49 AM
Reposted by Susie Shapiro
Paper in this week's NEJM shows that in patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy is superior to the combination of edoxaban plus an antiplatelet drug. Major difference was in bleeding rather than reduction in ischaemic events.
December 4, 2024 at 11:25 PM
Really proud of our physio Steph! Thank you to UK Haemophilia Society, Ben and others for this lovely recognition of her care and support! @ouhospitals.bsky.social www.ouh.nhs.uk/news/article...
Award-winning physiotherapist celebrated for ‘outstanding’ care - Oxford University Hospitals
Award-winning physiotherapist celebrated for ‘outstanding’ care
www.ouh.nhs.uk
December 4, 2024 at 7:19 AM
Reposted by Susie Shapiro
Tons of NEW DATA about andexanet, presented as part of FDA hearing last week. If you couldn’t make it through the short 6h meeting, GOOD NEWS, I’ve watched it and highlighted the important points.
A🧵
November 25, 2024 at 11:03 PM
Reposted by Susie Shapiro
⌛The countdown is on!
The ISTH 2025 abstract submission portal opens Nov 29.
Join us for ##ISTH2025 in Washington DC & plan to showcase your research on the global stage.
🗓️Abstract submission deadline is Jan. 15!
💡http://isth2025.org/abstracts
##HemeSky
November 26, 2024 at 3:25 PM
Reposted by Susie Shapiro
The World Federation of #Hemophilia 2023 Annual Global Survey was published today. These are the best international data on inherited bleeding disorders. Europe and the Americas have 28% of the world population and use 79% of the world's FVIII concentrate. tinyurl.com/4muevre6
November 26, 2024 at 9:31 PM
Reposted by Susie Shapiro
Wow! PETS has closed after recruiting over 11,000 because the research Q as to the benefit of stockings in low risk surgical pts has been answered. We wont know the answer until completed analysis & then publication in 2025
The largest ever trial on stocking!
November 21, 2024 at 3:20 PM
Really exciting to have gene therapy for haemophilia B as an option in the UK. It needed us to establish new models of care to ensure access and safety. UK guidance for implementation of gene therapy just published: doi.org/10.1111/hae....
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
Introduction 2022 was a landmark year with two adeno-associated viral vectors (AAVs) receiving conditional marketing authorization from EMA for the treatment of persons with severe haemophilia A and.....
doi.org
November 20, 2024 at 8:41 PM